California Depo-Provera Lawsuit

Nadrich Accident Injury Lawyers is representing those who have developed meningiomas or other conditions after receiving injections of Depo-Provera. We help victims of Depo-Provera recover financial compensation for medical bills, lost wages, loss of earning capacity, pain, suffering, wrongful death and more. Call us today for a free consultation if you or a loved one:

• Received Depo-Provera injections
• Developed meningioma (brain or spinal tumor), seizures, vision problems, bone density loss, headaches, or osteoporosis

Depo-Provera (medroxyprogesterone acetate) is a popular injectable birth control administered every three months. The contraceptive injection contains the hormone progestin and is widely used to suppress the menstrual cycle along with several types of negative menstrual conditions and side effects. However, recent studies have linked Depo-Provera to an increased risk for developing meningiomas. Depo-Provera lawsuits are being filed on behalf of women who used the medication and subsequently developed meningiomas or other conditions. Pharmaceutical company Pfizer failed to properly advise both doctors and patients about the risk. As an increasing number of tumor cases arise, it becomes clear that sufficient warning and long-term health studies were not pursued. 

If you have developed a meningioma tumor or another condition after taking Depo-Provera, you may be eligible to file a lawsuit to seek compensation for the harm and suffering you have experienced. Anyone who has used Depo-Provera for at least one year and has received treatment for a meningioma is eligible for a free case review with our lawyers. OurCalifornia Depo-Provera lawsuit attorneys can help you.

Call us now at 800-718-4658 for a free consultation to see if you have a qualifying Depo-Provera claim.

Grounds for Lawsuits

• Meningioma risks: According to a 2024 study, Depo-Provera is linked with a significantly higher risk of developing a meningioma, which is a head tumor which can necessitate surgery.
• Failure to Warn: Meningioma patients are alleging that Pfizer didn’t adequately warn about the meningioma risk associated with the drug, despite knowing about it.
• Withholding Information: Lawsuits are claiming that Pfizer withheld important information and failed to publicly warn about Depo-Provera’s risks.

Important Considerations

• Statute of limitations: Time limits exist for filing lawsuits. It is vital to promptly consult with an attorney.
• Symptom severity: The impact and extent of your meningioma symptoms will significantly affect the value of your case.
• Legal experience: It is crucial to consult with a lawyer with experience handling drug injury and product liability cases if you want to recover compensation.

Table of Contents

• Depo-Provera and Meningiomas
• Am I Eligible to File a Depo-Provera Lawsuit?
• Why Choose Nadrich Accident Injury Lawyers?
• What Is Depo-Provera?
• Side Effects of Depo-Provera 
• What to Do If You’ve Been Affected
• Filing a Depo-Provera Lawsuit
• Gathering Evidence for a Depo-Provera Lawsuit
• How Much Is a Depo-Provera Settlement Worth?
• Who Isn’t Eligible for a Lawsuit?
• Depo-Provera Statute of Limitations to File a Claim
• Who Manufactures Depo-Provera?
• Contact a Depo-Provera Lawsuit Attorney Today
• Depo-Provera Lawsuit Updates

Depo-Provera and Meningiomas

Lawyers have been prompted by a recent study to investigate claims made by women who ended up developing meningiomas following Depo-Provera injections. The drug, which has been sold as birth control in the United States since 1992, doesn’t carry warnings about a brain tumor risk. Luckily, the study failed to find malignant tumors in users of the contraceptive.

Meningiomas, however, are still capable of impacting nearby nerves, blood vessels and brain tissue, possibly causing serious disability. When this happens, the tumor may need to be removed surgically, and there are significant risks associated with brain surgery.

To qualify for our legal partners to file a lawsuit for you, you need to meet certain criteria, including the length of time you used the drug, how many shots you received and a specific diagnosis.

Every state gives a time limit for filing a claim known as a statute of limitations. Be sure to contact a lawyer immediately to preserve the legal right you have to file your claim.

Am I Eligible to File a Depo-Provera Lawsuit?

Eligibility for a Depo-Provera lawsuit is determined by three key factors: Usage, diagnosis, and other considerations.

• Usage – Must have used Depo-Provera or an authorized generic version at least twice.
• Diagnosis – Must have been diagnosed with a meningioma (brain or spinal tumor), seizures, vision problems, bone density loss, headaches, or osteoporosis after using Depo-Provera
• Other factors – Date of last Depo-Provera use and date of diagnosis

Contact us now to see if you have a qualifying claim.

Why Choose Nadrich Accident Injury Lawyers?

• Experience with pharmaceutical litigation: Our team has vast experience handling dangerous drug claims. We understand these cases’ nuances and know how to fight to protect your legal rights.
• No upfront fee: We are contingency fee lawyers. This means you don’t pay anything, not even case expense costs, until and unless we recover money for you.
• Compassionate service: Our lawyers provide each client with personalized attention. We make sure your needs get met and your questions get answered.
• Comprehensive evaluation of your case: We will perform a thorough medical records review to build the strongest case possible.
• Aggressive representation: Our attorneys are experienced and will tirelessly fight to recover the most compensation possible for you.

What Is Depo-Provera?

Depo-Provera is a progestin injection used for birth control, menstrual suppression, and management of negative menstrual symptoms. It prevents pregnancy by preventing eggs from developing and increases cervical mucus to prevent sperm from traveling toward an egg. 

“Depo” is a popular birth control alternative administered once every three months. Many women prefer the solution because it does not require pills or a patch. However, long-term use is not advised due to risks of permanent bone density loss and increased risk of breast cancer associated with most progestin-based hormonal birth control. Depo Provera is also known to cause typical birth control issues like weight changes and depression.

Side Effects of Depo-Provera 

Some common side effects that results from Depo-Provera usage includes headache, weight gain, changes in mood, period changes, decreased libido and more. In more severe cases, one might experience bloating and nausea, bone density loss, acne and other side effects. In rare cases, severe side effects such as menstrual changes, depression, blood clotting, brain tumors and more might occur.

Meningiomas

Unfortunately, one of the side effects of Depo-Provera birth control is an increased risk of tumors of the brain and spinal cord. The British Medical Journal reports that Depo-Provera increases the risk of intracranial meningiomas by 5.6 times if the birth control medication is used for over a year. Considering that many women choose it as their primary form of birth control, the risk of meningiomas can increase over time.

Progestin-related drugs, along with other hormone therapy medications like medrogestone and Promegestone, also increase the risk of intracranial meningiomas. Pfizer is aware of the risks of long-term progestogens, but women and their doctors were not adequately warned about the risks before Depo-Provera is prescribed.

What to Do If You’ve Been Affected

Symptoms of brain and spinal tumors include severe headaches, vision changes, hearing loss, memory loss, and loss of smell. Fatigue and seizures may also occur. If you’ve experienced these symptoms or been diagnosed with meningiomas or another condition after using Depo-Provera, take steps to protect your health. You may have a valid claim against Pfizer, the medication’s manufacturer.

Here’s what you should do:

• Seek medical attention – Get your condition diagnosed and seek treatment. Take care of yourself and put your health first.
• Talk to a Depo-Provera attorney – Discuss the potential of your case to make medical claims if you believe that Depo-Provera may have been the source of your condition and you weren’t properly warned it could happen.

Key Steps

1. Consult with an attorney: Those who have received Depo-Provera injections and received a meningioma diagnosis should consult with an attorney who handles pharmaceutical and product liability cases.
2. Case evaluation: Attorneys will assess your case, including your medical history and your diagnosis’ timing, to determine if you are eligible to file a Depo-Provera lawsuit.
3. Collect evidence: If your case is deemed eligible, our legal team will collect evidence, including expert testimony and medical records, to strengthen your claim.
4. File your lawsuit: We will file a lawsuit against Pfizer, seeking compensation for your injuries.
5. Negotiation and litigation: Our legal team will perform negotiations with Pfizer to come to a settlement. If we can’t reach a settlement, your case could proceed to trial, where we will represent you.

Filing a Depo-Provera Lawsuit

The first step to filing a Depo-Provera brain tumor lawsuit or spinal tumor lawsuit is to work with a personal injury attorney. Look for someone who specializes in medical cases, as fighting a pharmaceutical manufacturer is a complex and critical task, especially concerning a case type which will probably involve a multidistrict litigation in the future like this one. Together, you will build a case of medical evidence regarding how your birth control shot use likely caused your current medical condition, the severity of your condition, and the compensation that could be reached as a settlement if your case succeeds.

Gathering Evidence for a Depo-Provera Lawsuit

Collecting the evidence needed to prove your claim is vital. Evidence which might strengthen your case includes prescription records, comprehensive medical records, financial records which prove damages, witness and personal testimony, as well as proof that the medication you took was Depo-Provera or a generic which is authorized.

Don’t worry — you do not need to have all of this evidence and documentation before you call us. If you have a qualifying claim, we will request records on your behalf, and guide the collection of evidence. We provide the below details for informational purposes to show you how we will prove our client’s case.

Evidence needed for Depo-Provera lawsuits includes:

• Documentation of use of Depo-Provera: Medical records, such as doctor’s notes and prescription records, which demonstrate you received Depo-Provera, an authorized generic or depo-SubQ at least twice.
• Records of diagnosis: Proof that you were diagnosed with a meningioma or other condition, including CT or MRI scan results, pathology reports, and oncologist or neurologist records which show your diagnosis happened after you started Depo-Provera.
• Records of treatment: Documentation that you received treatment for your tumor, like medication, radiation therapy or surgery.
• Prescription and pharmacy records: Records which show that Depo-Provera or an authorized generic was dispensed, and which establish frequency of use and a timeline of use.
• Witness testimony: Statements from coworkers, friends or family explaining how your life has been impacted.
• Your testimony: Your personal account of your use of Depo-Provera, your symptoms’ onset, and how the condition has affected your life, including loss of income, pain and suffering.
• Financial records: These document your economic losses relating to lost wages, medical bills and additional expenses which relate to your condition.
• Impact upon your quality of life: This involves evidence which shows how your quality of life has been affected by your condition, including psychological trauma, loss of enjoyment or work incapacity.
• Event timeline: A clear timeline which links you starting Depo-Provera, the diagnosis of the condition, and the progression of the condition.
• Verification of the involvement of a defendant: Evidence that the drug you used was Depo-Provera made by Pfizer, or, alternately, an authorized generic is important to establish who the defendant is in your lawsuit.

How Much Is a Depo-Provera Settlement Worth?

The total amount that you might receive as a Depo-Provera settlement varies from case to case. However, certain conditions will be considered, including both your financial losses and the emotional impact that the loss has caused.

The following factors will impact your settlement value:

• Medical expenses – The cost of doctor’s visits, scans, and medical treatments.
• Long-term recovery costs – The cost of future treatments and medical care during recovery.
• Lost wages – Wages lost due to the illness taking you away from work.
• Lost earning potential – Loss of the ability to earn at your full capacity.
• Pain and suffering – The suffering and harm you experienced as a result of the illness.
• Loss of consortium – Loss of the ability to participate as a full member of your household.

In addition to the amount of money you lost to the illness, your lawyer may also seek punitive damages on your behalf as part of a Depo-Provera shot lawsuit.

Potential Damages

• Medical expenses: Plaintiffs may recover costs associated with treatment, diagnosis and ongoing care of meningioma tumors.
• Lost wages: Income lost due to an inability to work during recovery and treatment.
• Emotional distress: Reduced quality of life and psychological impact due to treatment and diagnosis.

Who Isn’t Eligible for a Lawsuit?

Not every individual who has taken injectable birth control is going to qualify to file a Depo-Provera lawsuit. As an example, patients who only took unauthorized generic or non-brand versions, did not use the drug sufficiently, received diagnoses prior to use of Depo-Provera, or have been diagnosed with pre-existing neurological problems may not qualify to recover compensation.

Exclusions for eligibility for a lawsuit include:

• Insufficient use: Those who have used the product less than two times might get excluded.
• Diagnosis prior to use: Those diagnosed with a meningioma or other condition before using the drug might not qualify.
• No diagnosis: Those who haven’t been diagnosed with a meningioma tumor or other condition might not qualify despite other symptoms.
• Usage of additional contraceptives: Those whose diagnosis might be explained by other hormonal medications or contraceptives might get excluded.
• Conditions which are pre-existing: Those with a history of meningiomas, brain tumors or additional neurological conditions which predate their Depo-Provera use might not qualify.
• Other diagnoses: Those diagnosed with neurological conditions or brain tumors which are not related to Depo-Provera or progestin might get excluded.
• Restrictions related to timeframe: A time limit may exist regarding how long after your last usage of the drug a diagnosis needs to be made in order to qualify. Diagnoses made after this timeframe might result in you getting excluded from a lawsuit.

Contact us to see if you qualify. It takes less than 5 minutes. 

Depo-Provera Statute of Limitations to File a Claim

The statute of limitations in a dangerous drug lawsuit will vary from state to state. Depending on the patient’s state of use or residence, the timeline may start from the date of discovery of injury, but may be extended in certain instances. The statute of limitations might start when the condition gets diagnosed, or when the patient learns that their condition could be caused by prior Depo-Provera usage. There may also be different claim filing deadlines for wrongful death claims, where a family member’s death was caused by a meningioma tumor.

Since the statute of limitations can vary significantly in these cases, it’s essential to contact an attorney handling Depo-Provera claims. A lawyer can help make sure your lawsuit is filed on time, and help with gathering the right documentation to build your case.

Our experienced team of birth control lawsuit attorneys have handled other dangerous drug claims, including Mirena IUD, Paragard IUD, Ortho-Evra, Yaz/Yasmine, and much more. 

Contact us now for a free, confidential consultation. See if you have a case by completing the contact form or calling us at 800-718-4658.

While our firm is based in California, our legal teams handle Depo-Provera claims nationwide.

Do not delay, contact us today to see if you qualify for a Depo-Provera lawsuit.

Who Manufactures Depo-Provera?

Pfizer is a pharmaceutical company based in New York. The company is known for medications such as Zoloft, Xanax, Viagra and Advil, as well as its COVID-19 vaccine. Pfizer saw the second largest revenue of any pharmaceutical company in 2020.

Pfizer was founded over 150 years ago and its triumphs include discovery of citric acid as well as mass production of vitamin C and penicillin.

However, the company has also been the subject of numerous lawsuits alleging they sold defective medications. The company has also been charged with healthcare fraud by the United States government.

In May 2024, it was reported that Pfizer would pay as much as $250 million to settle lawsuits which allege that the company failed to warn the public that Zantac could cause cancer.

In 2013, the company paid out a $273 settlement over lawsuits which alleged that Chantix provoked homicidal and suicidal thoughts, severe psychological disorders and self-harm.

In 2012, Pfizer paid out about $1 billion in order to settle lawsuits which claimed that Prempro caused patients to develop breast cancer.

In 2011, Pfizer had to compensate families of children who were killed in a drug trial in Africa. This drug trial involved giving one group of children their new drug and another group of children a conventional antibiotic. It was alleged that Pfizer intentionally gave the control group less of the conventional antibiotic than recommended to make their new drug appear more effective, and it was alleged that six children died because of this.

In 2009, Pfizer paid out a $2.3 billion settlement over falsely promoting Zyvox, Lyrica Pregabalin, Geodon capsules and Bextra valdecoxib tablets.

In 2004, Pfizer paid out a $430 million settlement over the off-label promotion of Neurontin.

In 1986, Pfizer needed to withdraw from the market their artificial heart valve because its defects caused it to be implicated in excess of 300 deaths. The company ended up paying out hundreds of millions of dollars due to lawsuits.

Contact a Depo-Provera Lawsuit Attorney Today

If you have been affected by the Depo-Provera brain tumor risk or another condition, don’t hesitate to call Nadrich Law to explore your legal options. We’ll help you put together a case based on your eligibility and the total impact that the illness has had on your life as a result of Depo-Provera.

Please fill out the free case evaluation form on this page. Our legal team will promptly respond to your request.

Depo-Provera Lawsuit Updates

August 12, 2026 Update

The process towards reaching a Depo-Provera settlement has taken a concrete step. BrownGreer has been appointed as settlement administrator after lawyers reached an agreement which should provide many women with pending MDL cases an opportunity to see their claims resolved.

BrownGreer is going to essentially run the settlement’s mechanics. It will review documents like medical records, collect information from plaintiffs as well as their attorneys, help to implement an allocation system, determine who is and isn’t eligible to participate, provide information necessary to issue payments, and coordinate settlement paperwork.

We don’t yet know the compensation tiers, settlement amounts, which plaintiffs will qualify, or the medical proof requirements. However, the infrastructure necessary to process as well as pay these claims is being put in place now.

We are still accepting new cases.

August 4, 2026 Update

Lawyers have finished working out the details of a settlement agreement which seeks to resolve pending Depo-Provera lawsuits brought by women who claim the drug caused them to develop meningioma brain tumors.

However, information regarding the settlement won’t get presented until the scheduling of a town hall meeting.

According to a case management order issued on July 27, the court overseeing the litigation was briefed on details of the settlement agreement, such as eligibility requirements, but noted that this settlement includes a confidentiality agreement which prevents that information from getting released to the public.

The order has noted that detailed information on the settlement will get presented to plaintiffs at a town hall meeting in the future. However, no scheduled date is given for that meeting by the order.

According to the order, settlement registration should get completed in November of 2026, with the claims process starting to get completed and payments starting to roll out by 2027’s first quarter.

July 28, 2026 Update

New lawsuits are still being filed despite the recently announced agreement in principle.

A complaint that was filed recently claims a woman developed a brain tumor after receiving injections of Depo-Provera without being warned that her risk of developing a meningioma tumor could increase.

She claims she wouldn’t have chosen to receive the injections if she had been warned adequately.

She claims damages including permanent physical deficits, lost income, medical expenses, a need for surgery, medication or other treatment, and reduced earning capacity.

Continued filings demonstrate why victims shouldn’t assume that the proposed settlement will automatically cover unfiled claims. Final deadlines and participation rules haven’t yet been made public.

July 13, 2026 Update

A lawsuit filed on July 6 by a Kansas woman alleges the woman developed an intracranial meningioma after she received injections of Depo-Provera for contraception.

The woman claims she first received the drug in approximately 2021 in Kansas and kept receiving injections there. She claims she received shots of brand-name Depo-Provera in approximately 2021 and 2022, and didn’t initially experience symptoms suggestive of a brain tumor.

She allegedly ended up with alarming symptoms in 2025, such as headaches, vision loss, dizziness and vertigo, leading to an MRI and a CT scan which revealed her brain tumor.

The woman claims the tumor has led to:

• Vision loss
• Hearing loss
• Mental anguish
• Persistent headaches
• Economic damages
• Diagnostic testing
• Other injuries

The lawsuit alleges that Indivior claimed through advertising, patient inserts, packaging and labeling that Depo-Provera is safe and appropriate while not warning patients and doctors that long-term usage of the drug could lead to a higher risk of developing an intracranial meningioma.

There are now 5,830 federal lawsuits pending in the Depo-Provera MDL.

June 15, 2026 Update

The judge overseeing the Depo-Provera MDL has been advised that the parties have reached an agreement in principle in order to resolve eligible pending claims in the MDL. The court then vacated deadlines which were associated with the initial bellwether trial.

The judge reset a preemption and general causation hearing for July 27 while the parties worked regarding final settlement documents. This hearing is important since no finalized settlement, allocation or claims process has yet been announced.

This agreement is a big step towards resolution. It isn’t, however, a public promise that every claimant will be paid.

Eligibility, payment tiers, deadlines, releases, deductions and proof requirements will determine what this agreement means for each plaintiff.

June 7, 2026 Update

A lawsuit filed in Florida by a Tennessee woman on June 1 alleges the woman was permanently injured after receiving injections of Depo-Provera which caused her to develop a pituitary meningioma that needed to be removed via brain surgery.

The lawsuit names Pharmacia LLC, Pharmacia & Upjohn Co. LLC and Pfizer Inc. as defendants.

The lawsuit alleges that a link was established between Depo-Provera and brain tumors by scientific studies years prior to the injections reaching the market, and that while the woman and other patients didn’t know this, Pfizer did.

According to the lawsuit, the woman started receiving injections of the drug in 1995 and kept receiving them until 2000.

The woman allegedly discovered she had a pituitary meningioma after having a CT scan done in July 2025. This is a type of brain tumor which develops next to the optic nerves and pituitary gland. She needed brain surgery in January of 2026 to remove the tumor.

After the surgery as well as the recovery period, the woman was allegedly left with cognitive impairment, a lost sense of smell and debilitating migraines which could possibly last for the remainder of her life.

The lawsuit indicates that while adequate warnings may have led her to choosing another type of contraception, manufacturers instead prioritized profit over the safety of patients and downplayed the drug’s risks.

May 18, 2026 Update

There are now over 6,000 Depo-Provera lawsuits in federal and state courts around the country.

The lawsuits involve claims that women ended up with intracranial meningioma brain tumors after receiving injections of the popular birth control medication.

A joint status report that was issued on May 15 in the Depo-Provera MDL indicated that there are currently:

• 5,549 lawsuits in the federal MDL
• 340 lawsuits in Delaware
• 119 claims in New York
• 91 lawsuits in California
• 72 claims in Minnesota
• 13 lawsuits in Connecticut
• 12 claims in Illinois
• Two lawsuits in New Mexico
• One claim each in New Hampshire, Wisconsin and Missouri

There were only around 4,000 pending cases around the country in March, so the number has increased by about 50 percent since then.

The recent spike in filings is likely due to the fact that the two year anniversary of the study which first discovered a link between the drug and brain tumors is approaching, and this may trigger a statute of limitations for women in numerous states.

April 27, 2026 Update

A lawsuit filed on April 13 in Florida by an Alabama woman alleges that she as well as millions of other women should have been warned that Depo-Provera is linked with a higher risk of developing an intracranial meningioma.

The lawsuit alleges that Pharmacia LLC, Pharmacia & Upjohn Co. LLC and Pfizer Inc. failed to warn the public about a risk of brain tumors and failed to design a product that is reasonably safe.

The lawsuit claims that the woman started receiving injections of Depo-Provera in 2007, continuing to use it through 2025. The woman was diagnosed with a meningioma in 2020, but, according to the lawsuit, she and her doctor didn’t know that the tumor may be linked to the drug since the label of the drug failed to adequately warn about the link.

The lawsuit alleges that scientific evidence that suggests that Depo-Provera can interact with meningioma receptors was ignored by Pfizer, who failed to warn about the potential link between the drug and brain tumors despite knowing about this evidence.

The lawsuit claims that Pfizer knew about the potential link since at least 1983.

February 20, 2026 Update

A lawsuit was filed on February 16 in New York by a New York woman who alleges that she developed a meningioma brain tumor due to long-term Depo-Provera usage. The lawsuit argues the medication is unreasonably dangerous and wasn’t sold with adequate side effect warnings.

The lawsuit names Pharmacia & Upjohn LLC, Pharmacia LLC and Pfizer Inc. as defendants.

The lawsuit joins almost 2,100 Depo-Provera lawsuits filed around the nation. The lawsuits allege that the drug’s manufacturers did not properly inform the public about a possible link between the drug and brain tumor risks.

The lawsuit alleges the woman was diagnosed with the tumor in July 2022 and now must live with a debilitating, life-long condition.

The lawsuit claims that the defendants knew or should have known for many years that the drug could stimulate the growth of tumors, yet didn’t adequately warn the public even while label changes were occurring in Canada, the EU and the UK.

The lawsuit claims that proper tumor risk warnings would have changed her decision to take the drug or prompted more close monitoring for neurological issues. She argues the diagnosis as well as the treatment have led to lost income, medical expenses and lost quality of life.

January 21, 2026 Update

A lawsuit filed on January 16 in Florida alleges that a woman developed headaches, memory loss and dizziness due to a brain tumor which was the result of receiving injections of Depo-Provera.

The lawsuit alleges that defendants Pharmacia LLC, Pharmacia & Upjohn LLC and Pfizer Inc. knew that the injections could cause interacranial meningioma brain tumors but failed to warn the public or medical community about this risk in order to profit.

The lawsuit joins over 2,100 Depo-Provera lawsuits that claim the defendants failed to warn about the brain tumor risk.

The woman allegedly started receiving the injections in 1992 and continued receiving them until 1995.

She allegedly started developing dizziness, headaches and memory loss, leading to a 2002 CT scan which revealed the tumor.

The tumor was surgically removed in October 2002.

The lawsuit claims that the woman wasn’t aware the tumor could have been caused by Depo-Provera until a study was published in 2024.

The lawsuit accuses the defendants of acting with reckless intent, wanton disregard and malice.

January 8, 2026 Update

A lawsuit filed in Delaware on December 26 by a Tennessee woman alleges that she developed a meningioma brain tumor in 2008, yet didn’t learn that it might have been caused by Depo-Provera for almost two decades.

The lawsuit names Pharmacia & Upjohn Company LLC, Pharmacia LLC and Pfizer Inc. as defendants, alleging they didn’t warn her or the medical community regarding risks associated with the drug.

Pfizer as well as generic manufacturers now face over 2,100 lawsuits brought by women who allege that the manufacturers failed to warn them about brain tumor risks.

The woman alleges she first received a Depo-Provera injection in the year 2004, then was diagnosed with a brain tumor in 2008, going through a brain surgery that year.

The woman claims that, having not been warned about a possible link between the drug and the tumor, she kept receiving injections of the drug until 2017.

The woman needed a second surgery in 2013 when the tumor returned, and needed a third procedure in 2014.

The lawsuit alleges the woman has suffered vision loss.

The lawsuit is indicating that the woman will require life-long medical monitoring.

December 30, 2025 Update

The judge presiding over the federal Depo-Provera MDL has called for the first proposed bellwether case to be ready for trial by, at the latest, early or mid-December 2026, indicating the rest of the bellwether trials will be scheduled for 2027.

The judge has indicated she wants the first trial set for December 7 or 14 in 2026, with the remainder of the trials beginning in January of 2027.

The judge indicated that the first bellwether trial will involve a Florida woman who claims she suffered hearing loss, dizziness and vertigo due to a brain tumor that was caused by Depo-Provera injections, leading to a necessary brain surgery.

December 19, 2025 Update

Federal regulators have approved a new update to Depo-Provera’s warning label.

The new warning label will read that meningioma cases have been reported after repeated administration of the drug, mostly regarding long-term use.

The label will instruct doctors to monitor patients for the symptoms of signs of meningioma brain tumors, and to discontinue the drug if a meningioma diagnosis occurs.

The label contains information which lawsuits allege should have been provided by Pfizer years ago.

December 15, 2025 Update

A lawsuit filed on December 9 in Florida alleges that a woman developed a meningioma brain tumor which was caused by her receiving shots of Depo-Provera.

The lawsuit alleges that Pfizer Inc., Pharmacia LLC and Pharmacia & Upjohn Co. LLC knew or should have known that the drug could cause brain tumors but withheld information and warnings from the medical community and consumers for decades.

The lawsuit alleges that the woman received shots of the medication from the early 2000s until 2013. According to the lawsuit, recent years saw the woman suffering increasing health issues, including neurological impairment and pain. Doctors allegedly eventually discovered she had a brain tumor in June 2024 after she had an MRI.

Doctors, by July 2025, warned the woman that the tumor was growing and may need to be surgically removed.

The lawsuit alleges that the woman might suffer more complications and injuries if the tumor continues to grow.

December 10, 2025 Update

The judge presiding over the Depo-Provera MDL has released a timeline for figuring out if plaintiffs possess reliable enough of evidence that the drug causes brain tumors to let the cases proceed.

Key deadlines for the bellwether trials were outlined by a December 12 scheduling order, including:

• January 1, 2026 for plaintiffs identifying witnesses and disclosing general causation experts
• February 9, 2026 for defendants disclosing experts regarding refutation of general causation
• March 20, 2026 for general causation expert depositions to be completed by
• April 22, 2026 for motions to be filed challenging admissibility of general causation opinions or experts
• May 1, 2026 for opposition filings

The court, following these deadlines, will determine if each side has convincingly established that their expert opinions are reliable enough to let the jury hear them during the bellwether trials.

It is being expected that this ruling may occur in the middle of 2026, meaning the first Depo-Provera trial in the MDL may begin at the end of 2026.

December 1, 2025 Update

The judge presiding over the Depo-Provera MDL has scheduled monthly status conferences in order to keep the litigation on track and the court updated.

Case management conferences have been scheduled for every month in 2026. The conferences will oversee the complicated legal proceedings, making sure the court stays updated on key developments such as discovery.

The parties have been ordered to prepare five bellwether trials which are designed to let the parties see how juries will likely respond to arguments, testimony and evidence that will probably be repeated through the whole litigation.

The plaintiffs need to, as part of preparing for the bellwether trials, demonstrate the scientific feasibility of Depo-Provera causing brain tumors. This is called general causation. Motions which challenge expert testimony regarding general causation have a deadline of March 22, 2026.

The bellwether trials will proceed if the plaintiffs can establish that there’s enough evidence to possibly convince a jury of Depo-Provera causing brain tumors.

November 6, 2025 Update

The judge presiding over the federal Depo-Provera MDL has granted the parties’ request for more time for general causation work to be completed for numerous bellwether trials that are being prepared for early 2026.

The plaintiffs and defendants had asked for the general causation process to be extended by an additional six weeks to sync up with New York and Delaware courts.

The request has been granted. Plaintiffs’ general causation experts need to be disclosed by December 1 now, and the defendants’ by January 9 of 2026.

All general causation expert depositions must be done by February 20, 2026 now, and all Rule 702 motions which challenge general causation expert testimony must be filed by March 22.

October 23, 2025 Update

A federal court and lawyers are seeking more coordination with related New York and Delaware state court cases. They have proposed a unified schedule regarding pretrial proceedings which are intended to test general causation regarding a link between Depo-Provera and brain tumors.

There are currently 1,346 pending cases in the MDL, as well as 70 cases in New York and 10 cases in Delaware.

In addition, 20 cases have been filed in California, six cases in Illinois, and a single case each in New Mexico and Connecticut.

The defendants and plaintiffs have both recommended that the MDL court work more closely with the judges overseeing the cases in New York and Delaware so everybody works on the same things at the same times for the sake of efficiency.

If the proposal is approved, all of the courts would follow the same schedule.

October 3, 2025 Update

A lawsuit was filed in Florida on September 26 by a California woman who alleges that she developed an intracranial meningioma brain tumor because she took Depo-Provera.

The lawsuit alleges she would have chosen a different type of birth control had Pfizer warned her that the drug was linked with a higher risk of developing brain tumors.

The woman allegedly started receiving shots of the drug in 1996, continuing to receive them until 2011.

The woman allegedly developed debilitating, severe neurological complications including tingling and numbness, and was diagnosed with a brain tumor in 2015.

After surgical removal of the tumor, she allegedly suffered a post-operation infection, necessitating additional brain surgery.

According to the lawsuit, she will need treatment and medical monitoring for the remainder of her life.

The lawsuit alleges that Pfizer knew that the drug was linked with a higher risk of brain tumors prior to the injections even being sold, yet failed to warn about the risk.

September 5, 2025 Update

A new study found that women over the age of 31 who receive injections of Depo Provera, as well as women who stay on the medication for many years, face higher risks of developing a brain tumor than other women.

The study found that the highest meningioma risks are seen in women over 31 and women who use the drug at least four years.

The study examined data from over 10 million women.

The study found that women who use Depo Provera have 2.43 times the risk of developing an intracranial meningioma than those who don’t.

The researchers estimated that Depo-Provera leads to an additional meningioma case for every 1,152 women who use the drug. Over 70 million U.S. women are believed to have received injections of the drug. This suggests that thousands of women may have developed preventable brain tumors.

August 14, 2025 Update

A lawsuit filed on August 12 in Florida by an Ohio woman alleges that Depo-Provera caused a woman to develop a brain tumor and that she will require medical tests and scans for the rest of her life to monitor for a return of the tumor.

The lawsuit names Pharmacia LL, Pharmacia & Upjohn, LLC and Pfizer, Inc. as defendants.

The lawsuit alleges that the defendants knew or should have known that the use of Depo-Provera could lead to brain tumors, but didn’t warn the medical community or patients about this risk.

The woman allegedly started experiencing tinnitus, seizures, balancing issues and headaches after receiving injections of Depo-Provera, and was diagnosed with a meningioma brain tumor in 2023, undergoing surgery to resection it.

While the surgery was successful, the woman will need regular CT scans and MRIs for the rest of her life.

August 1, 2025 Update

The judge presiding over the Depo-Provera MDL has ordered lawyers for the plaintiffs to disclose the number of unfiled meningioma claims, suggesting the lawyers are holding back on filing a substantial amount of lawsuits until critical rulings are given later this year on preemption motions.

The MDL currently contains over 550 lawsuits alleging that Depo-Provera users have developed meningioma brain tumors.

One primary defense that Pfizer has raised is an argument that federal law preempts failure to warn claims. The argument claims that Pfizer wasn’t able to strengthen the drug’s warning label.

The judge overseeing the MDL is expected to rule on this defense by the end of 2025.

In a July 14 case management order, the judge made the expectation “explicit” that lawyers who were selected for leadership roles in the MDL would file their cases promptly.

On July 16, the judge issued a pretrial order which called the apparent strategy of delaying the filing of claims until the preemption defense is ruled on “disruptive.” The judge has ordered lawyers appointed to leadership positions to certify how many Depo-Provera lawsuits remain unfiled by July 31.

July 14, 2025 Update

A new study adds to the growing body of scientific research showing that Depo-Provera injections increase the risk of women developing meningioma brain tumors.

The study includes data which indicates that Depo-Provera use triples the risk of developing meningioma brain tumors.

The researchers found that women who used Depo-Provera had 3.55 times the risk of developing a meningioma than women who used ethinylestradiol-levonorgestrel birth control pills.

Over 400 lawsuits have been filed over Depo-Provera allegedly causing brain tumors since a March 2024 study linked the shots with brain tumor risks.

July 6, 2025 Update

A wrongful death lawsuit was filed on July 1 in Florida by a Texas woman who alleges that her sister died from an intracranial meningioma because Depo-Provera’s makers failed to warn women about a brain tumor risk associated with the drug.

The lawsuit names Pfizer, Pharmacia LLC and Pharmacia & Upjohn Co. LLC as defendants.

The lawsuit alleges the deceased received injections of Depo-Provera from 2006 until she died in October 2024.

According to the lawsuit, the deceased, who died at the age of 47, had an autopsy done after death. The autopsy allegedly discovered that she died due to brain bleeding caused by the meningioma.

The lawsuit is one of over 400 Depo-Provera lawsuits which have been filed in federal court. It is expected that the litigation may eventually involve thousands of cases.

June 23, 2025 Update

A Colorado woman filed a lawsuit on June 17 in Florida alleging that she developed a brain tumor, blurred vision, dizziness and painful headaches because she received injections of Depo-Provera.

The woman allegedly began receiving injections of the drug in 2000, and continued to receive them until 2012.

The lawsuit notes that the active ingredient in Depo-Provera, depo medroxyprogesterone acetate (DMPA), has, for a long time, been linked to a higher risk of developing a meningioma tumor because brain tumors have many progesterone receptors.

The lawsuit alleges that researchers have known about a link between meningiomas and progesterone-inhibiting agents like Depo-Provera since at least 1989.

The woman allegedly found out about her brain tumor when she received a brain scan in 2021 after being physically assaulted. The lawsuit claims she wasn’t aware of the link between Depo-Provera and her brain tumor until 2025.

The woman allegedly suffers from headaches, weakness, dizziness, cognitive issues, difficulty speaking and blurry vision.

June 15, 2025 Update

On June 11, the judge overseeing the Depo-Provera MDL issued a case management order in order to summarize what parties discussed during a May 30 case management conference, issues that got resolved, and outstanding matters.

According to the order, a minimum of 75 percent of claims which are pending in federal court were filed since March 2025.

The litigation, according to the order, is growing rapidly, with around 300 lawsuits filed since March. The total was 405 at the time of the May 30 conference.

It was indicated by the judge that production of documents has proceeded as expected. Final deadlines for documents regarding general causation and preemption passed on May 11.

It was suggested by the order that defendants other than Pfizer might get dismissed soon. The order stated that the plaintiffs have indicated that they anticipated that defendants who make authorized generic versions of the drug will be dismissed soon.

Bellwether trials in the litigation are expected to begin by late 2026 or early 2027.

May 26, 2025 Update

While lawsuits are continuing to be filed over Depo-Provera’s brain tumor risks, Depo Sub-Q Provera 104 is gaining attention.

This is a low-dose alternative which was already on the market. It delivers 104 mg of the active ingredient via a subcutaneous injection, as opposed to traditional Depo-Provera’s 150 mg intramuscular injection.

Numerous experts think this alternative version may have significantly reduced meningioma risks in users via limiting cumulative exposure to the drug. However, despite this alternative version possibly being safer, Pfizer didn’t do much to transition users to the alternative version.

Lawyers for plaintiffs in the Depo-Provera litigation are arguing that this decision was a business one by Pfizer rather than a medical one. Replacing Depo-Provera, which had brand recognition and a market share that was well-established, could have led to less profits.

The fact that an under-promoted, viable alternative existed will probably become a key issue in terms of proving that Depo-Provera contained a design defect.

May 17, 2025 Update

Specific criteria have been set for plaintiffs in the Depo-Provera MDL to establish what form of birth control they took and what type of brain tumor they were diagnosed with.

May 12 saw the judge overseeing the MDL issue a pretrial order which outlines the process regarding identifying possible deficiencies in claims made by plaintiffs.

Plaintiffs in the MDL now must have been diagnosed with one of the following kinds of brain tumors:

• Meningioma
• Intercranial meningioma
• Intracranial meningioma
• Brain meningioma
• Cranial meningioma
• Arachnoid tumor
• Meninges tumor
• Falcine meningioma
• Convexity meningioma
• Intraventricular meningioma
• Parasagittal meningioma
• Skull base meningioma
• Olfactory groove meningioma
• Sphenoid wing meningioma
• Suprasellar meningioma
• Posterior fossa/petrous meningioma
• Foramen magnum meningioma
• Recurrent meningioma
• Fibrous meningioma
• Meningothelial meningioma
• Angiomatous meningioma
• Psammomatous meningioma
• Secretory meningioma

In addition, it now must be indicated by plaintiffs that their injury was due to, or exacerbated by, one of these versions of Depo-Provera:

• Depo-Provera
• Depo-Provera IM
• Depo-Provera Contraceptive Injection
• Medroxyprogesterone acetate
• Depo Medroxyprogesterone acetate
• Greenstone Medroxyprogesterone
• Depo-SubQ Provera 104
• Prasco MPA
• Prasco Medroxyprogesterone
• Greenstone MPA

March 31, 2025 Update

The Depo Provera MDL is moving quite quickly.

The MDL was created on February 7 and we are already seeing the second conference regarding case management, numerous pretrial orders having been put in place, as well as a clear discovery roadmap. This is a very fast timeline for a mass tort.

Defendants’ general causation and preemption document production is due by May 11. Preemption discovery will wrap up by the end of July. August will see preemption summary judgment motions and early 2026 will see general causation expert discovery get completed.

The MDL is not getting bogged down by endless negotiations or procedural delays. Discovery is moving quickly, a tight schedule has been set for preemption motions, and the judge overseeing the MDL is clearly intent on not letting the litigation stall.

Pressure is going to quickly mount on Pfizer with the pace set by the judge. When bellwether trials get schedule, Pfizer will need to weigh a structured settlement against uncertain jury awards. Speed matters, so this early pace is vital for plaintiffs.

March 17, 2025 Update

The judge overseeing the Depo Provera MDL has finalized appointing lawyers who will serve on the counsel steering committee for the plaintiffs. This committee acts as a representative body for the MDL’s plaintiffs, making collective decisions for the plaintiffs.

The judge also issued an order which sets deadlines for the bellwether trials. July 25, 2025 has been set for discovery regarding federal preemption, and August 24, 2025 has been set for judgment motions regarding preemption summary. Fact discovery regarding general causation will close in October. Daubert motions regarding causation experts will be due in February 2026.

March 5, 2025 Update

A case report was published on February 21 detailing a possibly dangerous side effect of Depo-Provera called phlegmasia cerulea dolens. The condition is a severe, rare type of deep vein thrombosis which is linked with restricted blood flow from limbs.

The 21-year-old woman in the case reported suffered numerous pulmonary embolisms.

The woman suffered from swelling, pain and numbness in the lower extremities in addition to shortness of breath and chest pain after receiving an injection of Depo-Provera. Tests found she had numerous blood clots lodged into each of her lungs, requiring extensive medical treatment, including repeat thrombectomy with venoplasty, catheter-directed thrombolysis, and thrombectomy.

These findings come under two weeks after a study found that, out of all hormonal contraceptives, Depo-Provera has the highest risk of blood clots.

February 19, 2025 Update

The judge who was appointed to preside over the Depo-Provera MDL will meet with attorneys on Friday for a case management conference. It is expected that, during the conference, the court will discuss the facilitation of the just, economical and expeditious resolution of the litigation.

The judge has advised plaintiffs and defendants to prepare to discuss identification of major legal issues in the litigation, how to protect and preserve sensitive information, and an appropriate structure of leadership for the litigation.

On February 13, a separate pretrial order was also issued by the court which established filing and docketing procedures for the MDL.

The MDL is expected to ultimately include thousands of lawsuits.

In other news, a recent study found that birth control injections such as Depo-Provera pose the highest blood clot risk of any birth control methods.

The researchers found that while those who took birth control pills ended up with 10 extra blood clots per 10,000 person-years when compared to those not taking birth control, those who received shots of Depo-Provera ended up with 12 extra blood clots, those who used the patch or vaginal rings ended up with 8 extra blood clots, those who took progestin-only pills ended up with three extra blood clots, and those who used IUDs ended up with two extra blood clots.

In other news, February 7 saw a lawsuit filed in Louisiana by a Louisiana woman who claims that injections of Depo-Provera led her to experience vision changes prior to being diagnosed with a meningioma.

The lawsuit claims she received the injections from 2012 to 2024. The plaintiff allegedly, over time, developed symptoms which were alarming, including right ear pain, right-sided headaches and blurry vision. An eye exam allegedly confirmed her optic nerve was swollen. The plaintiff then allegedly had an MRI done in 2019 which found a meningioma brain tumor pressing against the woman’s optic sheath.

The woman then allegedly underwent brain surgery for tumor removal, leading to a long recovery involving her being unable to work. The woman allegedly still has balance problems.

However, the woman was allegedly unable to link her tumor to Depo-Provera until last year.

February 11, 2025 Update

A new study published on February 2 found that women who receive quarterly injections of Depo-Provera for over a year may face 3.55 times the risk of developing a meningioma brain tumor when compared to those who use specific oral contraceptives.

The study suggests that one out of each 1,111 who receive shots of Depo-Provera for at least one year may develop a meningioma.

The study examined over 72,000 recipients of Depo-Provera and over 247,000 recipients of birth control pills.

The researchers propose that Depo-Provera may cause meningiomas to form by stimulating tumor cell proliferation through hormone receptor binding, especially to progesterone receptors. The researchers state that when these receptors are activated, it initiates signalling pathways which enhance cellular survival and proliferation, leading to an environment which helps tumor growth.

February 10, 2025 Update

All Depo-Provera lawsuits which have been brought in federal court will now be part of a multidistrict litigation, thanks to a decision by the United States Judicial Panel on Multidistrict Litigation, which has decided on transfering the lawsuits to Florida’s Northern District. A single judge will oversee the litigation through its discovery and pretrial phases, helping to facilitate a possible settlement or alternative resolution to the claims.

Almost 70 lawsuits have already been filed alleging that women have developed meningioma tumors after using the popular birth control shot.

The MDL will help to reduce duplicate discovery, avoid pretrial rulings which are conflicting, and make things more convenient for parties, witnesses and the court system.

Judge M. Case Rodgers has been assigned the MDL, and has previous experience handling large product liability MDLs, such as the defective 3M earplug MDL.

December 2, 2024 Update

A request has been made to a federal judges’ panel to centralize and consolidate all lawsuits involving Depo-Provera before a single judge for coordinated pretrial and discovery proceedings. This is because all of the cases claim that meningioma brain tumors were caused by the birth control injection.

November 26 saw almost a dozen plaintiffs join together in order to file a motion to centralize Depo-Provera lawsuits in a multidistrict litigation, to be handled in California’s Northern District.

The plaintiffs note that each complaint raises common questions of law and fact, and that it is expected that the scope and size of the Depo-Provera litigation will dramatically increase in the next few months. Because of this, it is argued by the motion that, by forming an MDL, duplicative discovery regarding common issues can be prevented, contradicting rulings from multiple judges can be avoided, and things can be more convenient for the court system, witnesses and all parties.

Should the motion be granted, all future and current claims will be consolidated before a single judge for coordinated pretrial motions, discovery, and possibly a series of bellwether trials.

November 21, 2024 Update

A California woman filed a lawsuit in California on November 15 alleging that she developed a meningioma because she took Depo-Provera. The lawsuit alleges that the tumor was removed surgically in 2010, yet returned over 10 years later.

The lawsuit alleges that defendants including Pfizer as well as generic Depo-Provera distributors and manufacturers such as Kaiser Permanente, Viatris Inc., Prasco Labs, Greenstone LLC and Pharmacia & Upjohn should have taken more steps to warn about Depo-Provera’s link with brain tumors.

The lawsuit alleges the defendants knew or should have known that Depo-Provera could increase the risk of meningiomas, yet actively downplayed and concealed this risk via aggressive promotions and marketing.

The lawsuit alleges the woman started receiving injections of Depo-Provera in 1996, and continued to receive the injections until 2005. The woman allegedly was diagnosed with a meningioma in 2010 after developing memory loss, limb weakness, migraines and severe headaches.

The lawsuit alleges a “golf ball” sized tumor was removed from her brain in 2010, and that the tumor returned 11 years later. The lawsuit claims she has been left with injuries and has missed about a dozen weeks of work.

November 6, 2024 Update

A California woman filed a lawsuit in California on October 28 which alleges that she developed a meningioma brain tumor because she received shots of Depo Provera.

The lawsuit alleges that various companies who made and sold the drug and its generic versions did not adequately warn doctors and users of the risk of brain tumors associated with the drug.

The lawsuit alleges she needed a bifrontal craniotomy in order to remove the tumor, and even continued to receive the shots after this surgery since her doctors didn’t know the shots were connected to the tumor.

The woman, according to the lawsuit, began receiving the shots in 1999 and kept receiving them on a regular basis for 19 years, including shots of the brand name version as well as authorized generics.

The woman, according to the lawsuit, eventually developed symptoms such as persistent headaches, memory issues, lethargy and disorientation. The woman eventually got disoriented while she was driving, went to the ER and was diagnosed with a brain tumor.

The surgery to remove her tumor allegedly involved drilling holes into her skull, removing a section of bone from her skull, retracting the frontal brain lobes, then surgically removing as much tumor as was possible. Following the surgery, the removed part of the skull was secured back in place by a plate.

Following the surgery, the woman allegedly suffered from double vision and blurred vision caused by parts of the brain experiencing obstructed blood flow.

The lawsuit points out that while Depo Provera’s label has warned about brain tumor risks since 2015, the same warnings were not provided on the drug’s United States label, leading to most U.S. doctors not knowing about the risks.

The woman allegedly continues suffering from numerous impairments, including memory issues, anxiety, less sense of taste, and losing her sense of smell. The woman also needs medication to prevent seizures and needs to use a wheeled walker.

October 30, 2024 Update

A lawsuit filed by a California woman on October 24 in California alleges that the woman developed meningioma, a form of brain tumor, due to her use of Depo Provera. The lawsuit alleges the tumor is too dangerous to be removed by doctors.

The lawsuit names Pfizer Inc., Upjohn Co. LLC, Pharmacia, Pharmacia LLC, Prasco LLC, Greenstone LLC and Viatris Inc. as defendants. The lawsuit indicates the woman received injections of name brand Depo Provera in addition to authorized generic versions.

The lawsuit notes that while warning labels for the drug have warned about a brain tumor risk since 2015 in Canada, these warnings were not provided on warning labels in the United States.

The woman, according to the lawsuits, received 91 shots of the drug between 2000 and 2024. The woman allegedly started experiencing symptoms like blurred vision, vertigo, headaches, ear itching and lightheadedness, and after multiple medical visits regarding these symptoms, she was diagnosed with a meningioma in 2020.

As of September 2024, the tumor was allegedly 9 mm, and due to its calcified nature, it is allegedly too dangerous to surgically remove. Because of this, the woman has had to endure continuous headaches.

The lawsuit alleges the defendants knew or should have known about the brain tumor risk connected with the drug but failed to warn about it.

October 21, 2024 Update

A lawsuit filed on October 15 in Indiana alleges that a woman developed a large meningioma after receiving shots of Depo-Provera. The lawsuit alleges that since he woman wasn’t warned that the drug could cause brain tumors, she continued to get injections of the drug after surgical remover of the tumor, and that this led to aggressive regrowth of the tumor.

The lawsuit alleges that the drug’s makers knew or should have known that the drug leads to a higher risk of meningioma development, yet failed to warn users of the drug or the medical community of this risk.

The lawsuit alleges that the woman started receiving shots of the drug in 1995, and kept receiving them until October of 2018. The lawsuit indicates that side effects of the drug caused the woman to become dizzy and fall in 2008, leading to severe bruising, facial lacerations requiring 17 stitches, and a fractured vertebra.

Between 2015 and 2017 the woman allegedly suffered from excessive sleep, apathy, light sensitivity, dizziness, confusion, depression, irritability, frustration and incontinence. Testing eventually revealed the woman developed a large brain tumor known as a meningioma, and this tumor was removed surgically in 2017.

Around six months after the removal surgery, the tumor began aggressively regrowing, according to the lawsuit, necessitating 36 rounds of radiation treatment to stop the brain tumor’s growth.

October 3, 2024 Update

A lawsuit was filed in California on October 1 by a California woman who alleges that she developed a brain tumor called a Sylvian fissure meningioma at only 37 years old due to her use of Depo-Provera. The lawsuit claims the woman needed brain surgery in order to remove this tumor. The surgery was allegedly invasive, involving a deep scalp incision and the skull being cut open by a drill-like tool. Surgeons allegedly needed to remove a significant portion of tissue from around the woman’s brain and needed to replace it with tissue from a cow heart.

The lawsuit alleges that Pfizer knew or should have known that Depo-Provera can cause brain tumors but failed to warn about this risk. The lawsuit cites extensive research which shows that Depo-Provera’s active ingredient can increase the risk of tumors developing.

March 1, 2024 Update

A BMJ study has revealed that people using injectible medroxyprogesterone (like Depo-Provera) may have a higher risk of meningiomas. The primary claim for Depo-Provera lawsuits is failure to warn, in which the drug manufacturer Pfizer is identified as not having provided adequate warnings about risks associated with the drug that might have prevented its use in an informed patient decision.

December 1, 2020 Update

A study on meningioma (brain tumor) lawsuits has revealed a pattern of meningiomas in women who took Depo-Provera. The average meningioma lawsuit settlement was around $850,000, targeting failure to diagnose. There has since been a rise in Depo-Provera lawsuits regarding the development of meningiomas and the failure to inform patients of the risks.